MX2018012880A - Metodos para proporcionar arn de hebra sencilla. - Google Patents
Metodos para proporcionar arn de hebra sencilla.Info
- Publication number
- MX2018012880A MX2018012880A MX2018012880A MX2018012880A MX2018012880A MX 2018012880 A MX2018012880 A MX 2018012880A MX 2018012880 A MX2018012880 A MX 2018012880A MX 2018012880 A MX2018012880 A MX 2018012880A MX 2018012880 A MX2018012880 A MX 2018012880A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- rna
- hebra
- provide simple
- ssrna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a métodos para proporcionar ARN de hebra sencilla (ssARN). Además, la presente invención se refiere al ssARN que es obtenible por los métodos de la invención y el uso de dicho ssARN en terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016059056 | 2016-04-22 | ||
| PCT/EP2017/059293 WO2017182524A1 (en) | 2016-04-22 | 2017-04-19 | Methods for providing single-stranded rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018012880A true MX2018012880A (es) | 2019-03-28 |
Family
ID=58699087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012880A MX2018012880A (es) | 2016-04-22 | 2017-04-19 | Metodos para proporcionar arn de hebra sencilla. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20190153425A1 (es) |
| EP (2) | EP3445850B1 (es) |
| JP (2) | JP7000343B2 (es) |
| KR (2) | KR102378404B1 (es) |
| CN (1) | CN109072232B (es) |
| AU (1) | AU2017251983B2 (es) |
| BR (1) | BR112018069417A2 (es) |
| CA (1) | CA3020481A1 (es) |
| CY (1) | CY1124845T1 (es) |
| DK (1) | DK3445850T3 (es) |
| ES (1) | ES2900272T3 (es) |
| HR (1) | HRP20211745T1 (es) |
| HU (1) | HUE059314T2 (es) |
| IL (1) | IL262304A (es) |
| LT (1) | LT3445850T (es) |
| MA (1) | MA44732B1 (es) |
| MD (1) | MD3445850T2 (es) |
| MX (1) | MX2018012880A (es) |
| NZ (1) | NZ745940A (es) |
| PL (1) | PL3445850T3 (es) |
| PT (1) | PT3445850T (es) |
| RS (1) | RS62612B1 (es) |
| RU (2) | RU2021134269A (es) |
| SG (2) | SG10202010471UA (es) |
| SI (1) | SI3445850T1 (es) |
| SM (1) | SMT202100681T1 (es) |
| WO (1) | WO2017182524A1 (es) |
| ZA (2) | ZA201805949B (es) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ745940A (en) | 2016-04-22 | 2025-06-27 | BioNTech SE | Methods for providing single-stranded rna |
| WO2018188730A1 (en) * | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Rna for treatment of autoimmune diseases |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| EP3938507A4 (en) | 2019-03-11 | 2023-02-22 | ModernaTX, Inc. | PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION |
| JP7740988B2 (ja) * | 2019-03-12 | 2025-09-17 | バイオエヌテック エスエー | 前立腺癌のための治療用ｒｎａ |
| US20220257631A1 (en) * | 2019-05-20 | 2022-08-18 | BioNTech SE | Therapeutic rna for ovarian cancer |
| CN114761555A (zh) | 2019-08-09 | 2022-07-15 | 胡桃钳医疗公司 | 用于从治疗性组合物中去除材料的制造方法和装置 |
| BR112022014513A2 (pt) * | 2020-02-07 | 2022-09-20 | Ultragenyx Pharmaceutical Inc | Agentes caotrópicos para reduzir a formação de rna de fita dupla |
| CA3167611A1 (en) | 2020-02-13 | 2021-08-19 | Etienne Simon-Loriere | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| CA3174588A1 (en) | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| SI3896159T1 (sl) * | 2020-04-17 | 2025-08-29 | Sartorius Bia Separations D.O.O. | Metoda čiščenja enoverižne rnk z uporabo anionskega izmenjevalca |
| SI3896160T1 (sl) * | 2020-04-17 | 2025-08-29 | Sartorius Bia Separations D.O.O. | Metoda čiščenja enoverižne rnk |
| EP3896161A1 (en) * | 2020-04-17 | 2021-10-20 | Bia Separations D.O.O. | A method of single-stranded rna purification |
| US20230174966A1 (en) | 2020-06-19 | 2023-06-08 | Etherna Immunotherapies Nv | Rna purification method |
| WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| JP2023546908A (ja) | 2020-10-14 | 2023-11-08 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | イオン化可能脂質ならびにその製造及び使用の方法 |
| WO2022218503A1 (en) | 2021-04-12 | 2022-10-20 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| WO2022101486A1 (en) | 2020-11-16 | 2022-05-19 | BioNTech SE | Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same |
| TW202237148A (zh) | 2020-11-16 | 2022-10-01 | 德商拜恩迪克公司 | 包含rna之lnp組合物以及製備、儲存及使用彼之方法 |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CN115197935B (zh) * | 2021-04-08 | 2025-10-21 | 上海细胞治疗集团股份有限公司 | 纤维素色谱纯化rna的方法 |
| EP4322925A2 (en) | 2021-04-12 | 2024-02-21 | BioNTech SE | Rna compositions comprising a buffer substance and methods for preparing, storing and using the same |
| US20240336672A1 (en) | 2021-04-26 | 2024-10-10 | Institut Pasteur | Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof |
| WO2022266038A1 (en) * | 2021-06-14 | 2022-12-22 | 2Seventy Bio, Inc. | Single stranded rna purification methods |
| WO2022266389A1 (en) * | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Alternative rna purification strategies |
| CN115505589B (zh) * | 2021-07-27 | 2025-07-25 | 上海兆维科技发展有限公司 | 一种rna的制备方法、合成蛋白质的方法以及转录反应液 |
| BR112024001180A2 (pt) | 2021-07-29 | 2024-04-30 | BioNTech SE | Composições e métodos para tratamento do melanoma |
| WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| US20240408032A1 (en) | 2021-09-10 | 2024-12-12 | BioNTech SE | Lipid-based rna formulations suitable for therapy |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| JP2024540948A (ja) | 2021-10-22 | 2024-11-06 | ビオンテック・ソシエタス・エウロパエア | 異なる投与のｒｎａを投与するための組成物 |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| IL312557A (en) * | 2021-11-08 | 2024-07-01 | Gritstone Bio Inc | Self-amplifying RNA compounds and methods of using them |
| WO2023083434A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2023126053A1 (en) | 2021-12-28 | 2023-07-06 | BioNTech SE | Lipid-based formulations for administration of rna |
| EP4469063A1 (en) | 2022-01-27 | 2024-12-04 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| JP2025508886A (ja) * | 2022-02-28 | 2025-04-10 | レヴィティ・ヘルス・サイエンシズ・インコーポレイテッド | 二本鎖及び一本鎖リボ核酸（ｒｎａ）を分離並びに検出する方法 |
| WO2023165681A1 (en) | 2022-03-01 | 2023-09-07 | BioNTech SE | Rna lipid nanoparticles (lnps) comprising a polyoxazoline and/or polyoxazine polymer |
| KR20230142248A (ko) | 2022-04-01 | 2023-10-11 | 주식회사 엘지에너지솔루션 | 연성회로기판을 포함하는 파우치형 전지셀 |
| WO2023193892A1 (en) | 2022-04-05 | 2023-10-12 | BioNTech SE | Nucleic acid compositions comprising an inorganic polyphosphate and methods for preparing, storing and using the same |
| JP2025516674A (ja) | 2022-05-13 | 2025-05-30 | ビオンテック エスエー | Ｈｉｖを標的とするｒｎａ組成物 |
| CN114921457B (zh) * | 2022-05-16 | 2023-09-29 | 硅羿科技（上海）有限公司 | 一种提取dsRNA的方法 |
| US20250319177A1 (en) | 2022-05-25 | 2025-10-16 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
| WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
| JP2025527245A (ja) | 2022-08-01 | 2025-08-20 | ビオンテック・ソシエタス・エウロパエア | 両親媒性オリゴエチレングリコール（ｏｅｇ）コンジュゲート化合物を含む核酸組成物およびそのような化合物および組成物を使用する方法 |
| WO2024027910A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | Rna for preventing or treating tuberculosis |
| CA3263686A1 (en) | 2022-08-03 | 2024-02-08 | BioNTech SE | RNA FOR THE PREVENTION OR TREATMENT OF TUBERCULOSIS |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| JP2025533527A (ja) | 2022-09-23 | 2025-10-07 | ビオンテック・ソシエタス・エウロパエア | Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法 |
| WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| AU2023357320A1 (en) | 2022-10-06 | 2025-04-17 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
| WO2024153324A1 (en) | 2023-01-18 | 2024-07-25 | BioNTech SE | Rna formulations for pharmaceutical use |
| WO2024180363A1 (en) | 2023-02-28 | 2024-09-06 | BioNTech SE | Linker sequence potency assays for multiple coding nucleic acids |
| WO2024180054A1 (en) | 2023-02-28 | 2024-09-06 | BioNTech SE | Linker sequence potency assays for multiple coding nucleic acids |
| EP4676598A1 (en) | 2023-03-09 | 2026-01-14 | BioNTech SE | Peptidoglycan hydrolases with bactericidal activity |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
| WO2024213776A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024216212A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024216214A1 (en) | 2023-04-14 | 2024-10-17 | BioNTech SE | Rna for preventing or treating tuberculosis |
| WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| WO2024228150A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| WO2024230783A1 (zh) * | 2023-05-11 | 2024-11-14 | 中国科学院过程工程研究所 | 一种在体外转录过程中减少或抑制双链核糖核酸形成的mRNA高产制备方法及试剂盒 |
| WO2024236192A1 (en) | 2023-05-17 | 2024-11-21 | Institut Pasteur | Heterodimer of poxvirus a16 and g9 proteins as an immunogen |
| WO2025003406A1 (en) | 2023-06-29 | 2025-01-02 | BioNTech SE | Modular multiplatform system for mrna drug production |
| WO2025024335A2 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| AU2024299365A1 (en) | 2023-07-24 | 2026-01-08 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025026866A1 (en) | 2023-07-28 | 2025-02-06 | BioNTech SE | Rna therapeutics with reduced toxicity |
| WO2025030097A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025027576A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
| WO2025051381A1 (en) | 2023-09-08 | 2025-03-13 | BioNTech SE | Methods and compositions for localized expression of administered rna |
| WO2025057088A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| EP4527937A1 (en) | 2023-09-20 | 2025-03-26 | BioNTech SE | One-pot in vitro transcription of multiple dna molecules to multiple rna molecules |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025078604A1 (en) | 2023-10-13 | 2025-04-17 | Smartcella Solutions Ab | Methods and compositions for delivery of unmodified mrna constructs using mesenchymal stem cells |
| GB202416789D0 (en) | 2023-11-15 | 2025-01-01 | BioNTech SE | SARS-COV-2 immunogenic compositions |
| WO2025133908A1 (en) * | 2023-12-20 | 2025-06-26 | Solventum Intellectual Properties Company | Method of separating nucleic acids |
| WO2025153707A1 (en) | 2024-01-19 | 2025-07-24 | Spikimm | Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| WO2025213131A1 (en) | 2024-04-05 | 2025-10-09 | BioNTech SE | Rna compositions for delivery of orthopox antigens and related methods |
| WO2025223684A1 (en) | 2024-04-23 | 2025-10-30 | BioNTech SE | Methods and compositions for stimulating immune response |
| WO2025264662A1 (en) | 2024-06-18 | 2025-12-26 | BioNTech SE | Compositions and methods for treatment of melanoma |
| WO2026015882A1 (en) | 2024-07-12 | 2026-01-15 | BioNTech SE | Hsv antigen fragments and related methods |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2936240A1 (de) * | 1979-09-07 | 1981-03-26 | Bayer Ag, 51373 Leverkusen | Verfahren zur herstellung bekannter und neuer 6-amino-6-desoxy-2,3-0-isopropyliden-(alpha)-l-sorbofuranose-derivate sowie neue zwischenprodukte des verfahrens |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| NL8900725A (nl) * | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| JP3692395B2 (ja) | 2000-09-01 | 2005-09-07 | 独立行政法人農業・生物系特定産業技術研究機構 | ベクターモノカリオンを用いた紫紋羽病菌に対するゲノムが２本鎖ｒｎａである糸状菌に寄生するウイルスを導入する新規方法 |
| US20050059024A1 (en) * | 2003-07-25 | 2005-03-17 | Ambion, Inc. | Methods and compositions for isolating small RNA molecules |
| WO2005012487A2 (en) * | 2003-08-01 | 2005-02-10 | Invitrogen Corporation | Compositions and methods for preparing short rna molecules and other nucleic acids |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2009528845A (ja) * | 2006-03-08 | 2009-08-13 | プロメガ・コーポレーション | 低分子量ｒｎａの精製方法 |
| CN101086011B (zh) * | 2006-06-08 | 2010-12-08 | 河南农业大学 | 食用菌和植物双链rna病毒检测试剂盒及其应用 |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| ES2500515T3 (es) | 2007-06-19 | 2014-09-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Síntesis y utilización de análogos de fosforotioato antiinversos de la caperuza de ARN mensajero |
| PL3112467T3 (pl) | 2009-12-07 | 2018-07-31 | The Trustees Of The University Of Pennsylvania | Preparaty RNA zawierające oczyszczony zmodyfikowany RNA do przeprogramowywania komórek |
| AU2012362113B2 (en) * | 2011-12-30 | 2017-08-03 | Cellscript, Llc | Making and using in vitro-synthesized ssRNA for introducing into mammalian cells to induce a biological or biochemical effect |
| PT4108769T (pt) * | 2015-05-29 | 2023-10-10 | Curevac Mfg Gmbh | Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial |
| NZ745940A (en) | 2016-04-22 | 2025-06-27 | BioNTech SE | Methods for providing single-stranded rna |
-
2017
- 2017-04-19 NZ NZ745940A patent/NZ745940A/en unknown
- 2017-04-19 PL PL17722695T patent/PL3445850T3/pl unknown
- 2017-04-19 MD MDE20190258T patent/MD3445850T2/ro unknown
- 2017-04-19 MX MX2018012880A patent/MX2018012880A/es unknown
- 2017-04-19 CN CN201780024328.9A patent/CN109072232B/zh active Active
- 2017-04-19 BR BR112018069417A patent/BR112018069417A2/pt not_active IP Right Cessation
- 2017-04-19 RU RU2021134269A patent/RU2021134269A/ru unknown
- 2017-04-19 EP EP17722695.8A patent/EP3445850B1/en active Active
- 2017-04-19 JP JP2018555164A patent/JP7000343B2/ja active Active
- 2017-04-19 SG SG10202010471UA patent/SG10202010471UA/en unknown
- 2017-04-19 KR KR1020187030368A patent/KR102378404B1/ko active Active
- 2017-04-19 LT LTEPPCT/EP2017/059293T patent/LT3445850T/lt unknown
- 2017-04-19 HR HRP20211745TT patent/HRP20211745T1/hr unknown
- 2017-04-19 MA MA44732A patent/MA44732B1/fr unknown
- 2017-04-19 ES ES17722695T patent/ES2900272T3/es active Active
- 2017-04-19 AU AU2017251983A patent/AU2017251983B2/en active Active
- 2017-04-19 PT PT177226958T patent/PT3445850T/pt unknown
- 2017-04-19 CA CA3020481A patent/CA3020481A1/en active Pending
- 2017-04-19 WO PCT/EP2017/059293 patent/WO2017182524A1/en not_active Ceased
- 2017-04-19 KR KR1020227009308A patent/KR102565881B1/ko active Active
- 2017-04-19 EP EP21204500.9A patent/EP4008782A1/en active Pending
- 2017-04-19 SI SI201730980T patent/SI3445850T1/sl unknown
- 2017-04-19 DK DK17722695.8T patent/DK3445850T3/da active
- 2017-04-19 HU HUE17722695A patent/HUE059314T2/hu unknown
- 2017-04-19 US US16/091,389 patent/US20190153425A1/en not_active Abandoned
- 2017-04-19 SM SM20210681T patent/SMT202100681T1/it unknown
- 2017-04-19 RS RS20211459A patent/RS62612B1/sr unknown
- 2017-04-19 RU RU2018136601A patent/RU2760790C2/ru active
- 2017-04-19 SG SG11201807573VA patent/SG11201807573VA/en unknown
-
2018
- 2018-09-05 ZA ZA2018/05949A patent/ZA201805949B/en unknown
- 2018-10-11 IL IL262304A patent/IL262304A/en unknown
-
2019
- 2019-08-22 ZA ZA2019/05536A patent/ZA201905536B/en unknown
-
2021
- 2021-11-26 CY CY20211101032T patent/CY1124845T1/el unknown
- 2021-12-23 JP JP2021209047A patent/JP7335313B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012880A (es) | Metodos para proporcionar arn de hebra sencilla. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| MX2021006053A (es) | Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas. | |
| MX2022009148A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
| GEP20217252B (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| TWD180147S (zh) | 淨水器 | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| MX381640B (es) | Metodos y compuestos agonistas de gip. | |
| TR201808169T3 (tr) | Rekombinant probiyotik bakteriler . | |
| PH12016501547A1 (en) | Anti-il-13/il-17 bispecific antibodies and uses thereof | |
| EA201692473A1 (ru) | Способы получения замещенных нуклеотидных аналогов | |
| CL2017002719A1 (es) | Imidazopirazinonas como inhibidores de pde1 | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| EA201991997A1 (ru) | Комбинированная терапия | |
| MX387421B (es) | Producción de virus en huevos aviares. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX376962B (es) | Nuevos compuestos macrociclicos. | |
| MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. | |
| CL2017002829A1 (es) | Sistemas y métodos para reducir las corrientes parásitas no deseadas. | |
| UY36602A (es) | Variantes de protoxina-ii y métodos de uso | |
| TWD180369S (zh) | 無儲水桶式逆滲透淨水器 | |
| CL2017002304A1 (es) | Métodos para tratar enfermedades | |
| MX375318B (es) | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. |